Zealand Pharma: first patient picked for extension trial
(CercleFinance.com) - A first patient will soon start the treatment developed by Zealand Pharma for short bowel syndrome as the Danish biotech firm kicks off its Phase 3 extension study on glepaglutide.
The Copenhagen-based company has enrolled the first patient in the study that was designed to evaluate the safety and efficacy of th drug over a two-year period, it said on Tuesday.
Patients who have completed the previous Phase 2 and Phase 3 trials for glepaglutide may be eligible to participate in the extension trial, Zealand said.
The pivotal trial with glepaglutide remains on track, it added, with results expected in 2020.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Copenhagen-based company has enrolled the first patient in the study that was designed to evaluate the safety and efficacy of th drug over a two-year period, it said on Tuesday.
Patients who have completed the previous Phase 2 and Phase 3 trials for glepaglutide may be eligible to participate in the extension trial, Zealand said.
The pivotal trial with glepaglutide remains on track, it added, with results expected in 2020.
Copyright (c) 2019 CercleFinance.com. All rights reserved.